The NIH requires authors of all publications resulting from any NIH-supported research to deposit the final accepted version of their manuscripts in PubMed Central. Cancer Research Frontiers will automatically make this deposit for the authors in PubMed Central, once our application would have been approved by US National Library of Medicine at 2020.
Cancer Research Frontiers would be indexed by PubMed, Google Scholar, the Chemical Abstracts Service, Index Copernicus, DOAJ, and OAJSE after several consecutive issues have been published, approximately by the end of 2020.
Although Cancer Research Frontiers does not now have an Impact Factor, it will work with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Cancer Research Frontiers will be available at 2022.
Digital Objective Identifier
Cancer Research Frontiers is a registered member of CrossRef and provides Digital Object Identifier (DOI) for all its published articles. DOI is a permanent unique identifier for an electronic document used to cite and link the published article electronically. The identifier will enable researchers or readers to electronically navigate published articles at a citation level irrespective of publisher or journal.
